MICROPORT (00853) announced the first-quarter 2026 results for Shanghai Microport Endovascular Medtech (Group) Co., Ltd. The subsidiary achieved revenue of RMB 370 million, representing an increase of 11.45% compared to the same period last year. Net profit attributable to equity holders of Shanghai Microport Endovascular Medtech reached RMB 155 million, a rise of 19.44% year-on-year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments